255 related articles for article (PubMed ID: 38004493)
1. Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment.
Morè S; Corvatta L; Manieri VM; Morsia E; Poloni A; Offidani M
Pharmaceuticals (Basel); 2023 Nov; 16(11):. PubMed ID: 38004493
[TBL] [Abstract][Full Text] [Related]
2. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
Landgren O; Nadeem O
Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
[TBL] [Abstract][Full Text] [Related]
3. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.
Offidani M; Corvatta L; Morè S; Olivieri A
Drug Des Devel Ther; 2021; 15():2401-2415. PubMed ID: 34103900
[TBL] [Abstract][Full Text] [Related]
4. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
Granger K; Gaffney KJ; Davis JA
J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
Zhao J; Ren Q; Liu X; Guo X; Song Y
J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma.
De Luca F; Allegra A; Di Chio C; Previti S; Zappalà M; Ettari R
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834545
[TBL] [Abstract][Full Text] [Related]
7. The emerging therapeutic landscape of relapsed/refractory multiple myeloma.
Tanenbaum B; Miett T; Patel SA
Ann Hematol; 2023 Jan; 102(1):1-11. PubMed ID: 36462062
[TBL] [Abstract][Full Text] [Related]
8. Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor.
Joseph NS; Tai YT; Anderson KC; Lonial S
Clin Pharmacol; 2021; 13():169-180. PubMed ID: 34434061
[TBL] [Abstract][Full Text] [Related]
9. Antibody-Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?
Ray U; Orlowski RZ
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111346
[TBL] [Abstract][Full Text] [Related]
10. Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody.
Pan D; Richter J
Cancer Manag Res; 2023; 15():741-751. PubMed ID: 37497430
[TBL] [Abstract][Full Text] [Related]
11. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
Tzogani K; Penttilä K; Lähteenvuo J; Lapveteläinen T; Lopez Anglada L; Prieto C; Garcia-Ochoa B; Enzmann H; Gisselbrecht C; Delgado J; Pignatti F
Oncologist; 2021 Jan; 26(1):70-76. PubMed ID: 33179377
[TBL] [Abstract][Full Text] [Related]
12. Antibodies and bispecifics for multiple myeloma: effective effector therapy.
Cipkar C; Chen C; Trudel S
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):163-172. PubMed ID: 36485135
[TBL] [Abstract][Full Text] [Related]
13. Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences.
Morè S; Offidani M; Corvatta L; Petrucci MT; Fazio F
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296910
[TBL] [Abstract][Full Text] [Related]
14. A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma.
Midha S; Hartley-Brown MA; Mo CC; Hossain S; Nadeem O; O'Donnell EK; Bianchi G; Sperling AS; Laubach JP; Richardson PG
Expert Opin Drug Saf; 2023; 22(11):1049-1071. PubMed ID: 37906232
[TBL] [Abstract][Full Text] [Related]
15. New and emerging pharmacotherapies for the management of multiple myeloma.
Moore DC; Oxencis CJ; Shank BR
Am J Health Syst Pharm; 2022 Jul; 79(14):1137-1145. PubMed ID: 35333922
[TBL] [Abstract][Full Text] [Related]
16. Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond.
Podar K; Leleu X
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680303
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future.
Abramson HN
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958658
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma.
Radocha J; van de Donk NWCJ; Weisel K
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33805481
[TBL] [Abstract][Full Text] [Related]
19. Antibody-Based Treatment Approaches in Multiple Myeloma.
Hosoya H; Sidana S
Curr Hematol Malig Rep; 2021 Apr; 16(2):183-191. PubMed ID: 33730360
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses.
Musto P; La Rocca F
Expert Rev Hematol; 2020 Apr; 13(4):331-349. PubMed ID: 32153224
[No Abstract] [Full Text] [Related]
[Next] [New Search]